home / stock / anab / anab short
Short Information | AnaptysBio Inc. (NASDAQ:ANAB)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 1,111,654 |
Total Actual Volume | 6,727,972 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 55,583 |
Average Short Percentage | 18.28% |
Is there a ANAB Short Squeeze or Breakout about to happen?
See the ANAB Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-08-2024 | $24.88 | $25.47 | $25.98 | $24.83 | 271,693 | 43,663 | 16.07% |
07-05-2024 | $24.9 | $24.75 | $25.04 | $24.39 | 148,546 | 31,946 | 21.51% |
07-03-2024 | $24.59 | $24.9 | $25.45 | $24.31 | 281,290 | 49,699 | 17.67% |
07-02-2024 | $24.42 | $23.94 | $24.76 | $23.72 | 249,252 | 59,462 | 23.86% |
07-01-2024 | $25 | $24.61 | $25.3334 | $24.4 | 191,145 | 49,375 | 25.83% |
06-28-2024 | $25 | $25.06 | $25.37 | $24.54 | 546,539 | 89,509 | 16.38% |
06-27-2024 | $24.36 | $24.8 | $24.85 | $23.86 | 119,278 | 15,390 | 12.9% |
06-26-2024 | $23.86 | $24.22 | $24.3 | $23.39 | 291,110 | 36,218 | 12.44% |
06-25-2024 | $23.92 | $23.85 | $24.09 | $23.63 | 203,439 | 43,999 | 21.63% |
06-24-2024 | $24.05 | $24.05 | $24.39 | $23.58 | 217,765 | 50,535 | 23.21% |
06-21-2024 | $23.17 | $24 | $24.6167 | $23.17 | 1,223,996 | 121,701 | 9.94% |
06-20-2024 | $22.97 | $22.89 | $23.3 | $22.26 | 479,252 | 111,684 | 23.3% |
06-18-2024 | $23.16 | $22.89 | $23.16 | $22.36 | 322,144 | 74,029 | 22.98% |
06-17-2024 | $23.81 | $23.38 | $23.93 | $22.87 | 181,939 | 26,025 | 14.3% |
06-14-2024 | $24.01 | $23.77 | $24.07 | $23.48 | 155,791 | 35,040 | 22.49% |
06-13-2024 | $23.98 | $24.25 | $24.55 | $23.71 | 193,034 | 55,444 | 28.72% |
06-12-2024 | $24.15 | $24.1 | $24.93 | $23.64 | 480,591 | 65,636 | 13.66% |
06-11-2024 | $23.43 | $23.65 | $24.4 | $22.94 | 433,142 | 51,097 | 11.8% |
06-10-2024 | $23.12 | $23.61 | $23.88 | $23.02 | 423,747 | 64,483 | 15.22% |
06-07-2024 | $23.84 | $23.43 | $24.09 | $23.17 | 314,279 | 36,719 | 11.68% |
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least 24 weeks maintained clear to almost clear skin and none experienced a flare ...